Total Neoadjuvant Therapy for Pancreatic Cancer—What Is Totality?
This article discusses the meaning of the word total in relation to total neoadjuvant therapy for pancreatic cancer.
Related Articles
The evolving use of selinexor in multiple myeloma
Meletios Dimopoulos, MD, National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the use of selinexor in the treatment of multiple myeloma,…
Self‐collected versus clinician‐collected anal swabs for anal cancer screening: A systematic review and meta‐analysis
The first international consensus guidelines for anal cancer screening of high-risk populations were published in 2024. Given barriers associated with anal swab collection, self-collection may…
Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer
Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.
NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma
An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.
Zeroing in on vaginal microbes that most increase HIV risk
The largest-ever study of women in sub-Saharan Africa zeroes in on the combination of bacterial vaginosis-associated bacteria and inflammatory proteins that raise the risk of…
IBI363 Receives FDA Fast Track Designation for Advanced/Metastatic Melanoma
The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.
Opinion | The Business of Health Care Depends on Exploiting Doctors and Nurses (Published 2019)
One resource seems infinite and free: the professionalism of caregivers.
Operating at a loss: Our health care system depends on physicians donating their time
Every doctor I asked told me they, too, were chronically behind and spent a few uncompensated hours outside of work each day catching up on…
A fresh look at covalent BTK inhibitor resistance
In this issue of Blood, Woyach et al present a beautiful study of mutational profiling for patients with relapsed or refractory chronic lymphocytic leukemi
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma
The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.